ATE400647T1 - C-terminale modifikation von polypeptiden - Google Patents

C-terminale modifikation von polypeptiden

Info

Publication number
ATE400647T1
ATE400647T1 AT05774367T AT05774367T ATE400647T1 AT E400647 T1 ATE400647 T1 AT E400647T1 AT 05774367 T AT05774367 T AT 05774367T AT 05774367 T AT05774367 T AT 05774367T AT E400647 T1 ATE400647 T1 AT E400647T1
Authority
AT
Austria
Prior art keywords
polypeptides
trypsin
xaa2
terminal modification
amino acid
Prior art date
Application number
AT05774367T
Other languages
English (en)
Inventor
Eva Hoess
Frank Bordusa
Rupert Herrmann
Hans-Dieter Jakubke
Wilhelm Tischer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE400647T1 publication Critical patent/ATE400647T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT05774367T 2004-08-13 2005-08-12 C-terminale modifikation von polypeptiden ATE400647T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04019237 2004-08-13

Publications (1)

Publication Number Publication Date
ATE400647T1 true ATE400647T1 (de) 2008-07-15

Family

ID=34926160

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05774367T ATE400647T1 (de) 2004-08-13 2005-08-12 C-terminale modifikation von polypeptiden

Country Status (9)

Country Link
US (2) US20080064079A1 (de)
EP (1) EP1778839B1 (de)
JP (1) JP4538501B2 (de)
CN (1) CN101010425B (de)
AT (1) ATE400647T1 (de)
CA (1) CA2569707C (de)
DE (1) DE602005008071D1 (de)
ES (1) ES2309785T3 (de)
WO (1) WO2006015879A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005046113A1 (de) 2005-09-27 2007-03-29 Sanofi-Aventis Deutschland Gmbh Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen
DE102006031955A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
DE102006031962A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
US20120093840A1 (en) 2009-04-06 2012-04-19 Novo Nordisk A/S Targeted delivery of factor viii proteins to platelets
KR101853606B1 (ko) 2009-07-06 2018-05-03 사노피-아벤티스 도이칠란트 게엠베하 메티오닌을 함유하는 수성 인슐린 제제
KR101337322B1 (ko) 2009-11-13 2013-12-06 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
DK2498802T3 (en) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
US9587006B2 (en) * 2010-02-11 2017-03-07 Hoffmann-La Roche Inc. IGF-I poly (ethylene glycol) conjugates
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PL2750699T3 (pl) 2011-08-29 2015-12-31 Sanofi Aventis Deutschland Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
SG11201605242YA (en) 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
AU2015359376B2 (en) 2014-12-12 2021-09-09 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
SI3793588T1 (sl) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Postopki zdravljenja hemofilije A
EP3650541A1 (de) 2018-11-08 2020-05-13 BioPharma Translationsinstitut Dessau Forschungs GmbH Trypsin-mutante zur c- und n-terminalen modifizierung von polypeptiden
CN113227369B (zh) * 2018-12-19 2025-09-12 生物制药翻译学院德绍研究有限公司 具有改善的酶学特性的胰蛋白酶变体
AU2020399194A1 (en) 2019-12-10 2022-07-28 Sanofi A method of forming a conjugate of a sulfonamide and a polypeptide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9001705D0 (sv) * 1990-05-11 1990-05-11 Medscand Ab Saett foer diagnostik av virusbaerande tumoerer genom immunoassay
US5580751A (en) * 1990-09-14 1996-12-03 Carlsberg A/S Process for the preparation of C-terminally amidated peptides
AU6171594A (en) 1993-02-04 1994-08-29 Genentech Inc. Serine protease variants having peptide ligase activity
US6187579B1 (en) * 1993-10-28 2001-02-13 Carlsberg A/S Customized proteases
EP0720614B1 (de) 1994-07-25 2000-05-24 Roche Diagnostics GmbH Metallkomplexe mit geladenem linker
US5985627A (en) 1997-02-28 1999-11-16 Carlsberg Laboratory Modified carboxypeptidase
DE10049673A1 (de) * 2000-10-07 2002-04-25 Univ Leipzig Verfahren zur Herstellung von Peptiden, Peptidmimetika und Proteinen
CN1354253A (zh) * 2001-12-24 2002-06-19 南京医科大学 淡色库蚊胰蛋白酶基因

Also Published As

Publication number Publication date
EP1778839A1 (de) 2007-05-02
WO2006015879A1 (en) 2006-02-16
JP2008508871A (ja) 2008-03-27
JP4538501B2 (ja) 2010-09-08
US20130177940A1 (en) 2013-07-11
CA2569707C (en) 2013-09-24
DE602005008071D1 (de) 2008-08-21
CN101010425A (zh) 2007-08-01
CA2569707A1 (en) 2006-02-16
US20080064079A1 (en) 2008-03-13
US8927230B2 (en) 2015-01-06
CN101010425B (zh) 2010-05-26
ES2309785T3 (es) 2008-12-16
HK1110888A1 (en) 2008-07-25
EP1778839B1 (de) 2008-07-09

Similar Documents

Publication Publication Date Title
DE602005008071D1 (de) C-terminale modifikation von polypeptiden
FR2831170B1 (fr) Proteines c modifiees activables directement par la thrombine
IL184112A0 (en) A method for producing polypeptides or proteins in a disulfide-bridged two-chain form
IN2014CN02050A (de)
DK1144607T5 (da) Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger
NO20074374L (no) Fremgangsmate for fremstilling av polypeptidblandinger ved anvendelse av hydrogenolyse
NZ593837A (en) Recombinantly modified plasmin
ES2534744T3 (es) Plasmina modificada de forma recombinante
MY148447A (en) Method for amidating polypeptides with basic aminoacid d-terminals by means of specific endoproteases
CA2443365A1 (en) Methods for the recombinant production of antifusogenic peptides
ATE398179T1 (de) Von rna polymerasen abstammende polypeptide und ihre verwendungen
MXPA03000786A (es) Peptidos de promiostatina y metodos de usar los mismos.
WO2005027953A3 (en) Use of proline specific endoproteases to hydrolyse peptides and proteins
ZA200500622B (en) Polypeptides with a signal sequence comprising an fivsi motif and olynucleotides encoding therefor
MX369317B (es) Vacunas contra el virus de la influenza y sus usos.
MX2018009216A (es) Metodo para producir un hidrolizado de proteina empleando una tripeptidil peptidasa de aspergillus fumigatus.
EP2014676A4 (de) Mutante des hgf-precursor-proteins und aktivierte form davon
EA200701778A1 (ru) Понижающие кровяное давление пептиды из гликомакропептида
DE602007010969D1 (de) Zytokinderivate
ATE477272T1 (de) Verwendung von stefin a als gerüstprotein
ES2072422T3 (es) Procedimiento para la produccion de peptidos amidados en alfa en el terminal c.
EP1796707A4 (de) Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren
ATE485831T1 (de) Behandlung von neurodegeneration
WO2019059709A3 (ko) Ｈｐ1404 펩타이드로부터 유래한 신규 항균 펩타이드 및 이의 용도
WO2003094972A3 (en) Fap-activated anti-tumor prodrugs

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1778839

Country of ref document: EP